Plate Nº 78 · recorded November 16, 2026

Health & Medicine ResearchReported finding

Stem Cell Infusion Cut Fractures 94% in Small Osteoporosis Trial

Ten women with advanced osteoporosis saw fractures drop 94% over two years after one infusion of engineered stem cells — but the small, uncontrolled trial leaves key questions open.

By Elena Vasquez4 min read700 words

In brief

  1. A single infusion of engineered MSCs cut fragility fractures by 94 percent over two years in 10 women over 50 with advanced osteoporosis.
  2. Fractures fell from an average of 8 per year before treatment to 0.5 per year afterward.
  3. Bone tissue area in biopsies rose about 70 percent four months after infusion; pain dropped 34 percent at two years.
  4. The trial, published in Cell, had no control group and did not track cells after infusion.
  5. A larger randomized trial at the University of Murcia will compare self-derived, donor-derived and no MSC treatment.
Breakthrough to Make Bones Stronger Has The Potential to Reverse Osteoporosis
Plate Nº 78Breakthrough to Make Bones Stronger Has The Potential to Reverse Osteoporosis — congerdesign / pixabay

A single infusion of engineered stem cells cut fragility fractures by 94 percent over two years in 10 women with advanced osteoporosis, according to a first-in-human trial published in Cell.

The patients, all women over 50, suffered an average of eight fractures per year in the two years before treatment. After receiving their own modified stem cells, that figure fell to 0.5 per year.

Osteoporosis is an incurable condition affecting millions worldwide, in which the body loses bone faster than it can replace it. The result is a skeleton prone to breaks. Preventing those fragility fractures is the foremost goal of every current osteoporosis therapy.

How does the treatment work?

The researchers, based in Spain, worked with mesenchymal stem/stromal cells, or MSCs — the primitive cells that develop into osteoblasts, which build and repair bone. Doctors can harvest MSCs from marrow, the spongy tissue at the center of bones, and grow them into large numbers in the lab.

Scientists have pursued this idea for years, but there has always been a catch. When MSCs are infused into the bloodstream of mice, very few reach the bone marrow where they are needed.

The Spanish team's fix: engineer the cells with a 'return address' for bone marrow, wrapping each one in a special sugar coating. In mice, sugar-coated MSCs can re-enter bone and generate new tissue. Whether the same homing happens in humans remains unproven, because the trial did not track the cells after infusion.

What did the trial actually measure?

Fractures were only part of the picture. Four months after infusion, bone biopsies showed the average area occupied by bone tissue had increased by roughly 70 percent. That opens the possibility the technique can reverse some osteoporosis-related bone loss, not merely slow it.

The trial also recorded statistically significant changes in bone turnover markers — chemicals in blood that signal bone formation and breakdown — and in bone mineral density. Bone formation markers stayed elevated for six months after the single dose.

Two years on, participants reported 34 percent less bone pain and a 30 percent reduction in disability scores.

The authors write that the fracture reduction could not be ascribed to lifestyle changes, adding: "Moreover, it cannot be attributed to medication modifications… since no fractures occurred throughout the post-infusion period in those patients."

Ajit Varki, a physician-scientist at UC San Diego who was not involved in the study, told Nature's Elie Dolgin the results are "quite remarkable." The trial, Varki said, "showed an almost 100 percent efficacy sustained for several years – and no side effects."

Why are experts urging caution?

No control group received a placebo. Most of the women were taking other osteoporosis drugs. All were enrolled at a moment of severe fracture trouble — and fracture risk naturally fluctuates, meaning a group measured at its worst may improve on its own.

Physician Jan Schaefer, writing on LinkedIn, called the work a "fascinating experiment" but said the verdict is a few years away. He also explained the core delivery problem: "MSCs are 20 to 30 micrometers across, larger than a lung capillary, so on the first pass through the circulation 50 to 80 percent of them lodge in the lungs. Of the rest, very few find their way into bone marrow on their own. You can have a potentially useful cell circulating and achieve almost nothing, because it never reaches the tissue you want to treat."

In short, fewer fractures does not prove the cells reached the bone. The study cannot say how many MSCs arrived or how long they survived.

One co-author, Robert Sackstein, holds intellectual-property rights to the cell-engineering technology used — a financial interest worth noting when weighing the findings.

What comes next?

Researchers at the University of Murcia in Spain are preparing a larger follow-up trial in patients with advanced osteoporosis. That study will randomly assign participants to one of three arms:

  • engineered MSCs grown from the patient's own bone marrow
  • engineered MSCs from a healthy donor
  • no MSC treatment at all

A controlled trial should settle whether the sugar-coating trick truly works in humans. Until then, the results are promising but preliminary.

via sciencealert.com (Source)

Filed under

  • osteoporosis
  • stem-cells
  • mesenchymal-stem-cells
  • fracture-prevention
  • clinical-trials
Share this article:

More from Elena Vasquez

Elena Vasquez

Show full bio

Correspondent covering money, funding and market shifts around general science news at SciBeat.

441 articles

Nearby plates

« Previous article